Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin’s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma
Authors:
Open Access
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Journal of Chromatography B
- Vol. 1164, 122486
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trialJournal of Psychopharmacology, 2016
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trialJournal of Psychopharmacology, 2016
- Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogensEuropean Neuropsychopharmacology, 2016
- Long-term follow-up of psilocybin-facilitated smoking cessationThe American Journal of Drug and Alcohol Abuse, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage CancerArchives of General Psychiatry, 2011
- Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive DisorderThe Journal of Clinical Psychiatry, 2006
- Response of cluster headache to psilocybin and LSDNeurology, 2006
- HallucinogensPharmacology & Therapeutics, 2004
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist actionNeuroReport, 1998
- Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen RauschpilzenHelvetica Chimica Acta, 1959